From Stem Cells to CAR-T: LivMedCell Expands Its Role in the Future of Medicine

^{Photo: LivMedCell via FL Communications}

ISTANBUL, July 08, 2025 (GLOBE NEWSWIRE) -- LivMedCell has officially launched a groundbreaking research collaboration with the University of Pennsylvania’s Perelman School of Medicine to advance CAR-T cell therapy and personalized oncology.

The agreement, signed in late May 2025, is being publicly announced today as part of LivMedCell’s strategic expansion beyond regenerative medicine.

This initiative marks a new chapter in LivMedCell’s commitment to next-generation cellular therapies and positions the center at the forefront of innovative immunotherapy research.

Located in Istanbul, LivMedCell is Turkey’s first and only hospital-based stem cell production center operating under Good Manufacturing Practices (GMP) standards. Since 2014, the center has treated thousands of patients from Europe, the Middle East, Central Asia, and beyond — offering personalized, Ministry of Health-approved cellular therapies for a wide range of chronic and degenerative conditions.

Science Meets Clinical Impact: A Global Reference in Regenerative Medicine

^{Photo: The expert team behind LivMedCell - Turkey’s pioneering center for stem cell therapies.}

Led by Prof. PhD. Erdal Karaöz — an internationally recognized expert in stem cell and regenerative medicine with over 300 scientific publications and multiple global awards — LivMedCell has established itself as a reference center in the field. In addition to directing LivMedCell, Prof. PhD. Karaöz also serves as a faculty member at Istinye University, where he continues his academic contributions through research, teaching, and innovation in cellular therapies.

LivMedCell provides personalized stem cell and exosome treatments for:

• Neurological conditions: stroke, autism, cerebral palsy, spinal cord injury
• Pulmonary diseases: COPD, IPF, post-COVID lung damage
• Cardiac issues: ischemic heart disease, diabetic foot
• Musculoskeletal injuries: cartilage damage, tendon tears, avascular necrosis
• Autoimmune disorders: multiple sclerosis, lupus, Crohn’s
• Aesthetic & dermatological applications: skin rejuvenation, hair loss, wound healing
• Endocrine and urological issues: type 1 diabetes, ovarian insufficiency, erectile dysfunction
  

^{Photo: LivMedCell}

Each therapy is manufactured under GMP conditions and administered with multidisciplinary clinical oversight — a unique model that ensures both safety and efficacy.

Redefining Longevity: A Scientific Approach to Youth and Vitality

In a world obsessed with appearance, LivMedCell’s Longevity Program goes beyond the surface. Backed by cellular science, this unique approach offers not just aesthetic results — but true cellular rejuvenation.

At the heart of the program is a simple yet powerful idea:

“Don’t just look young — be young.”

By using GMP-certified stem cells and exosomes, LivMedCell’s longevity treatments aim to renew the body from within, restore damaged tissue, regulate inflammation, and slow biological aging.

Looking Ahead: CAR-T Cell Therapy Collaboration with UPenn

^{Photo: The Liv Hospital and Penn Medicine teams celebrating the launch of their groundbreaking academic collaboration in Istanbul.}

Taking a bold step into next-generation cellular treatments, LivMedCell has initiated a research collaboration with the University of Pennsylvania (UPenn) — a global leader in CAR-T cell therapy. While regenerative medicine remains the core focus, this partnership marks a strategic expansion into immunotherapy and personalized oncology.

Media Contact:

FL PR and Communications

asset@flcommunications.co.uk

+905330202554

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/f85c9b27-3c9a-4cef-aebe-87019f1bafb3

https://www.globenewswire.com/NewsRoom/AttachmentNg/c292da7f-e559-4d38-978b-907ca5fbd70f

https://www.globenewswire.com/NewsRoom/AttachmentNg/ff9963d9-0f25-4ec0-bcfb-bf41477da0e7

https://www.globenewswire.com/NewsRoom/AttachmentNg/f8e6dacf-093c-45b8-a532-dbda6762da13

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.